Xolair Related Published Studies
Well-designed clinical trials related to Xolair (Omalizumab)
Omalizumab and the risk of malignancy: results from a pooled analysis. [2012]
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. [2011.09]
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. [2011.07]
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. [2011.05.03]
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. [2011.05]
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. [2011.03.17]
Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. [2011.02]
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in
patients with H1-antihistamine-refractory chronic idiopathic urticaria. [2011]
Omalizumab decreases IgE production in patients with allergic (IgE-mediated)
asthma; PKPD analysis of a biomarker, total IgE. [2011]
Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. [2010.12]
Omalizumab-induced decrease of FcvarepsilonRI expression in patients with severe allergic asthma. [2010.11]
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. [2010.06]
Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab. [2010.04]
Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. [2010.04]
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. [2010.02]
Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. [2010.02]
Omalizumab for pediatric asthma. [2010]
Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the
clinical course - a randomized, placebo-controlled and double blind pilot study. [Article in English, German] [2010]
Effects of omalizumab on basophil and mast cell responses using an intranasal cat
allergen challenge. [2010]
Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. [2010]
Safety of anti-IgE treatment with omalizumab in children with seasonal allergic
rhinitis undergoing specific immunotherapy simultaneously. [2010]
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. [2009.12]
Relationship between pretreatment specific IgE and the response to omalizumab therapy. [2009.12]
Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. [2009.11]
Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma. [2009.10]
The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. [2009.10]
Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. [2009.09.02]
Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma. [2009.09]
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. [2009.02]
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. [2009.01]
Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. [2008.05]
Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. [2008.02]
Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. [2008]
Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. [2007.10]
Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. [2007.09]
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. [2007.09]
Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. [2007.02]
[Omalizumab as a therapeutic option in atopic eczema : Current evidence and potential benefit.] [2007.02]
[Omalizumab as a therapeutic option in atopic eczema : Current evidence and potential benefit.] [2007.01.20]
Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. [2006.06]
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. [2006.01]
Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma. [2006]
Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. [2005.09]
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. [2005.03]
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. [2004.09.15]
Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. [2004.09]
Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. [2004.08]
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. [2004.07]
Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. [2004.07]
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. [2004.04]
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. [2004.04]
Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. [2004.04]
Omalizumab inhibits allergen challenge-induced nasal response. [2004.03]
Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. [2004.02]
Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. [2003.12]
Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab). [2003.10]
Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. [2003.08]
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. [2003.08]
Omalizumab is effective in the long-term control of severe allergic asthma. [2003.08]
Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. [2003.05]
Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. [2003.02]
Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. [2003.01]
The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. [2002.11]
Omalizumab improves asthma-related quality of life in children with allergic asthma. [2002.11]
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. [2002.07]
The effect of omalizumab on nasal allergic inflammation. [2002.07]
Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. [2001.12.19]
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. [2001.08]
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. [2001.08]
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). [2001.08]
Well-designed clinical trials possibly related to Xolair (Omalizumab)
Evaluating the minimally important difference of the urticaria activity score and
other measures of disease activity in patients with chronic idiopathic urticaria. [2012]
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. [2010.09]
Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. [2010.04]
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic
rhinosinusitis. [2010]
Decreases in human dendritic cell-dependent T(H)2-like responses after acute in
vivo IgE neutralization. [2010]
Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. [2008.04]
The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. [2006.09]
The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. [2004.09]
Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. [2004.07]
The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. [2002.11]
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. [2002.02]
Other research related to Xolair (Omalizumab)
Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. [2011.11]
Development of the Asthma Control Composite outcome measure to predict omalizumab response. [2011.09]
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. [2011.08]
Omalizumab in patients with severe asthma: the XCLUSIVE study. [2011.07.08]
[The efficacy of shortening an administration period with omalizumab]. [2011.05]
Safety of omalizumab in asthma. [2011.05]
Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. [2011.05]
Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma. [2011.04]
Omalizumab: Anti-IgE therapy in allergy. [2011.04]
Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. [2011.03]
Xolair in asthma therapy: an overview. [2011.02]
Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. [2011.01]
Omalizumab for the treatment of severe persistent allergic asthma in children
aged 6-11 years. [2011]
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. [2011]
Effects of omalizumab on changes in pulmonary function induced by controlled cat
room challenge. [2011]
Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma. [2010.12]
Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. [2010.07.30]
One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma. [2010.06]
Effects of omalizumab in patients with food allergy. [2010.01]
Immunological effects of omalizumab in chronic urticaria: a case report. [2010]
|
